Join the Breast Cancer group to help and get support from people like you.
Breast Cancer News (Page 13)
Related terms: Breast Cancer, inflammatory, Cancer, Breast, Carcinoma, Ductal, Carcinoma, Lobular, Ductal Carcinoma in Situ (DCIS), Ductal Carcinoma in Situ, DCIS
Too Many Breast Cancer Survivors Miss Out on Genetic Screening
FRIDAY, July 19, 2024 – Many breast cancer patients aren’t getting genetic counseling and testing that could help them get the most effective treatment, a new study finds. Only three-quarters of p...
Some Women in Their 40s Prefer to Delay Breast Cancer Screening
MONDAY, July 15, 2024 – A considerable proportion of women aged 39 to 49 years prefer to delay breast cancer screening, especially after a decision aid (DA) intervention, according to a study...
Hormone Therapy for Breast Cancer May Lower Dementia Risk
TUESDAY, July 16, 2024 – Hormone therapy for breast cancer might reduce a woman’s later risk of dementia and Alzheimer’s disease, a new study finds. Overall, hormone therapy is associated with a 7% l...
Shannen Doherty Dies of Breast Cancer at 53
MONDAY, July 15, 2024 – Actress Shannen Doherty, best known for her roles in 1990s television hits such as “Beverly Hills, 90210” and “Charmed," has died at 53 after a long struggle with breast cance...
FDA Approves Tepylute (thiotepa) Ready-to-Dilute Injectable Formulation to Treat Breast Cancer and Ovarian Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE) June 28, 2024 --Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has app...
FDA Approves Hercessi (trastuzumab-strf), a Biosimilar to Herceptin
DURHAM, N.C., April 29, 2024 /PRNewswire/ – Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care...
FDA Approves Lumisight (pegulicianine) Optical Imaging Agent to Illuminate Residual Breast Cancer Post-Lumpectomy
NEWTON, Mass.--(BUSINESS WIRE) April 18, 2024 --Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection...
FDA Approves Truqap (capivasertib) plus Faslodex for Patients with Advanced HR-Positive Breast Cancer
17 November 2023 – AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, ...
FDA Broadens Indication for Verzenio (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
INDIANAPOLIS, March 3, 2023 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio...
U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
First Trop-2 Directed ADC to Demonstrate Overall Survival Benefit in HR+/HER2- Metastatic Breast Cancer Patients who had Received Prior Endocrine-based Therapy and at Least Two Chemotherapies...
FDA Approves Orserdu (elacestrant) for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been...
Enhertu Approved in the US as the First HER2-Directed Therapy for Patients with HER2-Low Metastatic Breast Cancer
Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reduced risk of disease progression or death by 50% and increased overall survival by more than six months v...
Enhertu Approved in the US for Patients with HER2-Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Approval broadens indication for AstraZeneca and Daiichi Sankyo’s Enhertu to earlier use in metastatic breast cancer Based on ground-breaking DESTINY-Breast03 results showing Enhertu reduced the r...
Lynparza Approved in the US as Adjuvant Treatment for Patients with Germline BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
First and only approved medicine targeting BRCA mutations in early breast cancer New data show Lynparza demonstrated overall survival benefit in early breast cancer March 11, 2022 – A...
FDA Approves Verzenio (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
INDIANAPOLIS, Oct. 13, 2021 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine ...
Further information
Related condition support groups
Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer - Male, Cancer
Related drug support groups
methotrexate, fluorouracil, anastrozole, letrozole, Keytruda, Herceptin, Arimidex, doxorubicin, Femara, trastuzumab, tamoxifen, Ibrance, docetaxel